Figure 5 | Signal Transduction and Targeted Therapy

Figure 5

From: Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Figure 5

Distribution of trastuzumab, T-SA1 and T-SA2 in vivo was displayed by bioluminescence imaging system. Both T-SA1 and T-SA2 could target tumor tissues specifically within 2 h post injection and the maximum fluorescence intensity on the area of tumor was observed at 12 h post injection. The tumor tissue areas were shown with the red arrows. The liver areas were shown with the blue arrows.

Back to article page